Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1500

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2016. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

• Analysis of partnership and licensing deals based on clinical stage of development of products.

• Summary of the pharmaceutical deals globally in the five quarters.

• Information on the top deals happened in the pharmaceutical industry.

• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1Table of Contents

1Table of Contents2

1.1List of Tables7

1.2List of Figures11

2Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 201615

2.1Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 201615

2.2Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 201617

2.3Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 201618

2.4Pharmaceuticals & Healthcare, Global, Top Deals, Q1 201619

2.4.1Shire to Acquire Baxalta for USD32 Billion19

2.4.2Mylan to Acquire Meda for USD9.9 Billion21

2.4.3Abbott Labs to Acquire Alere23

2.4.4Sanofi Prices Public Offering of Notes for USD2 Billion24

2.4.5Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics24

3Pharmaceuticals & Healthcare, Global, Deals Summary, by Type26

3.1Pharmaceuticals & Healthcare, Global, M&A, Q1 201626

3.1.1Top M&A Deals in Q1 201627

3.1.2Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2015 – Q1 201628

3.2Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 201629

3.2.1Top Initial Public Offerings in Q1 201630

3.2.2Top Secondary Offerings in Q1 201631

3.2.3Top PIPE Deals in Q1 201631

3.2.4Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2015–Q1 201631

3.2.5Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2015 – Q1 201632

3.3Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 201633

3.3.1Top Venture Financing Deals in Q1 201634

3.3.2Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 201635

3.3.3Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 201636

3.3.4Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2015 – Q1 201637

3.3.5Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2015 – Q1 201638

3.3.6Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2015 – Q1 201639

3.4Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 201640

3.4.1Top Private Equity Deals in Q1 201641

3.4.2Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2015 – Q1 201642

4Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 201643

4.1Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 201643

4.2Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2015 – Q1 201645

4.3Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 201646

4.3.1Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 201647

4.3.2Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 201647

4.3.3Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 201648

4.4Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201649

4.5Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2015 – Q1 201651

4.6Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2015 – Q1 201652

4.7Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201654

5Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 201656

5.1Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 201656

5.2Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201658

5.2.1Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 201659

5.2.2Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 201660

5.2.3Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 201660

5.3Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2015 – Q1 201661

5.4Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 – Q1 201662

5.5Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 – Q1 201664

5.6Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2015 – Q1 201665

5.7Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2015 – Q1 201667

6Pharmaceuticals & Healthcare, Global, M&A Financial Analysis69

6.1Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2015 – Q1 201669

6.2Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2015 – Q1 201671

6.3Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 – Q1 201672

6.4Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 – Q1 201673

6.5Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2015 – Q1 201674

6.6Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 – Q1 201675

7Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area76

7.1Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 201676

7.1.1Oncology – Deals of the Quarter78

7.2Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 201680

7.2.1Central Nervous System – Deals of the Quarter81

7.3Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 201683

7.3.1Infectious Disease – Deals of the Quarter84

7.4Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 201687

7.4.1Immunology – Deals of the Quarter88

7.5Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 201690

7.5.1Metabolic Disorders – Deals of the Quarter91

7.6Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 201693

7.6.1Cardiovascular – Deals of the Quarter95

7.7Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 201697

7.7.1Gastrointestinal – Deals of the Quarter98

7.8Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q1 2016100

7.8.1Hematological Disorders – Deals of the Quarter101

7.9Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2016103

7.9.1Respiratory – Deals of the Quarter104

7.10Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2016106

7.10.1Dermatology – Deals of the Quarter107

8Deal Summary by Geography109

8.1Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2016109

8.1.1North America – Deals of the Quarter110

8.2Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2016112

8.2.1Europe – Deals of the Quarter113

8.3Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2016117

8.3.1Asia-Pacific – Deals of the Quarter118

8.4Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2016120

8.4.1Rest of the World – Deals of the Quarter121

9Pharmaceuticals & Healthcare, Global, Top Advisors123

9.1Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2015 – Q1 2016123

9.2Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2015 – Q1 2016125

10Appendix126

11Further Information128

11.1Methodology128

11.2About GlobalData129

11.3Disclosure information130

11.4Disclaimer130

Table

1.1List of Tables

Table 1:Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201616

Table 2:Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 201618

Table 3:Pharmaceuticals & Healthcare, Global, Top Deals, Q1 201619

Table 4:Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201627

Table 5:Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 201627

Table 6:Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q1 2015 – Q1 201628

Table 7:Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201630

Table 8:Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 201630

Table 9:Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 201631

Table 10:Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 201631

Table 11:Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2015–Q1 201631

Table 12:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201632

Table 13:Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201634

Table 14:Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 201634

Table 15:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 201636

Table 16:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201637

Table 17:Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201638

Table 18:Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2015 – Q1 201639

Table 19:Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201641

Table 20:Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 201641

Table 21:Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201642

Table 22:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201644

Table 23:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201645

Table 24:Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201646

Table 25:Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q1 201647

Table 26:Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 201647

Table 27:Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 201648

Table 28:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201650

Table 29:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 – Q1 201653

Table 30:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201655

Table 31:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201657

Table 32:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201659

Table 33:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 201659

Table 34:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 201660

Table 35:Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 201660

Table 36:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201661

Table 37:Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q1 2015 – Q1 201663

Table 38:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 – Q1 201666

Table 39:Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201668

Table 40:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 – Q1 201670

Table 41:Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 – Q1 201671

Table 42:Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 – Q1 201672

Table 43:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2015 – Q1 201673

Table 44:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 – Q1 201674

Table 45:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 – Q1 201675

Table 46:Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201677

Table 47:Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201681

Table 48:Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201684

Table 49:Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201688

Table 50:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201691

Table 51:Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201694

Table 52:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201698

Table 53:Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016101

Table 54:Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016104

Table 55:Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016107

Table 56:Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016110

Table 57:Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016113

Table 58:Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016118

Table 59:Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016121

Table 60:Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016124

Table 61:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016125

Table 62:Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q1 2015-Q1 2016126

Figures

1.2List of Figures

Figure 1:Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201615

Figure 2:Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 201617

Figure 3:Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 201618

Figure 4:Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q1 2015 – Q1 201626

Figure 5:Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2015 – Q1 201628

Figure 6:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201629

Figure 7:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q1 2015 – Q1 201632

Figure 8:Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201633

Figure 9:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 201635

Figure 10:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 201636

Figure 11:Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 – Q1 201637

Figure 12:Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201638

Figure 13:Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201640

Figure 14:Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2015 – Q1 201642

Figure 15:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201643

Figure 16:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201645

Figure 17:Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201646

Figure 18:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201649

Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 – Q1 201651

Figure 20:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2015 – Q1 201652

Figure 21:Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q1 2015 – Q1 201654

Figure 22:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201656

Figure 23:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201658

Figure 24:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201661

Figure 25:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201662

Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2015 – Q1 201664

Figure 27:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q1 2015 – Q1 201665

Figure 28:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2015 – Q1 201667

Figure 29:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2015 – Q1 201669

Figure 30:Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2015 – Q1 201671

Figure 31:Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2015 – Q1 201672

Figure 32:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2015 – Q1 201673

Figure 33:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2015 – Q1 201674

Figure 34:Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2015 – Q1 201675

Figure 35:Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201676

Figure 36:Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201680

Figure 37:Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201683

Figure 38:Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201687

Figure 39:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201690

Figure 40:Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201693

Figure 41:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 201697

Figure 42:Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016100

Figure 43:Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016103

Figure 44:Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016106

Figure 45:Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016109

Figure 46:Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016112

Figure 47:Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016117

Figure 48:Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016120

Figure 49:Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016123

Figure 50:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2015 – Q1 2016125

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016 thematic reports
Currency USD
$1,500

Can be used by individual purchaser only

$4,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016 in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2016 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.